
Paul Dorian

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6340607/publications.pdf Version: 2024-02-01



ΡΑΙΠ ΠΟΡΙΑΝ

#	Article	IF	CITATIONS
1	Prophylactic Use of an Implantable Cardioverter–Defibrillator after Acute Myocardial Infarction. New England Journal of Medicine, 2004, 351, 2481-2488.	27.0	1,358
2	2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2014, 30, 1114-1130.	1.7	382
3	Development and Validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in Patients With Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2011, 4, 15-25.	4.8	339
4	Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest. New England Journal of Medicine, 2016, 374, 1711-1722.	27.0	329
5	2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2016, 32, 1170-1185.	1.7	243
6	Evaluation of Early Complications Related to De Novo Cardioverter Defibrillator Implantation. Journal of the American College of Cardiology, 2010, 55, 774-782.	2.8	222
7	Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. American Heart Journal, 2002, 143, 984-990.	2.7	211
8	2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2018, 34, 1371-1392.	1.7	195
9	Prevention of Arrhythmia Device Infection Trial. Journal of the American College of Cardiology, 2018, 72, 3098-3109.	2.8	160
10	Atrial Premature Beats Predict Atrial Fibrillation in Cryptogenic Stroke. Stroke, 2015, 46, 936-941.	2.0	157
11	Increased atrial arrhythmia susceptibility induced by intense endurance exercise in mice requires TNFα. Nature Communications, 2015, 6, 6018.	12.8	148
12	Validation of a New Simple Scale to Measure Symptoms in Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 218-224.	4.8	145
13	Sudden Cardiac Arrest during Participation in Competitive Sports. New England Journal of Medicine, 2017, 377, 1943-1953.	27.0	143
14	Trends in Short- and Long-Term Survival Among Out-of-Hospital Cardiac Arrest Patients Alive at Hospital Arrival. Circulation, 2014, 130, 1883-1890.	1.6	130
15	Mechanisms Underlying the Lack of Effect of Implantable Cardioverter-Defibrillator Therapy on Mortality in High-Risk Patients With Recent Myocardial Infarction. Circulation, 2010, 122, 2645-2652.	1.6	126
16	Prevalence of Anginal Symptoms and Myocardial Ischemia and Their Effect on Clinical Outcomes in Outpatients With Stable Coronary Artery Disease. JAMA Internal Medicine, 2014, 174, 1651.	5.1	118
17	The Effect of Vernakalant (RSD1235), an Investigational Antiarrhythmic Agent, on Atrial Electrophysiology in Humans. Journal of Cardiovascular Pharmacology, 2007, 50, 35-40.	1.9	106
18	Quality of Life and Functional Capacity in Patients With Atrial Fibrillation and Congestive Heart Failure. Journal of the American College of Cardiology, 2013, 61, 455-460.	2.8	97

#	Article	IF	CITATIONS
19	The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications. Canadian Journal of Cardiology, 2015, 31, 3-16.	1.7	96
20	Risk Factors for Infections Involving Cardiac Implanted Electronic Devices. Journal of the American College of Cardiology, 2019, 74, 2845-2854.	2.8	94
21	Improving Temporal Trends in Survival and Neurological Outcomes After Out-of-Hospital Cardiac Arrest. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e003561.	2.2	91
22	Survival Benefit of the Primary Prevention Implantable Cardioverter-Defibrillator Among Older Patients. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 179-186.	2.2	90
23	Identifying Patients With Atrial Fibrillation in Administrative Data. Canadian Journal of Cardiology, 2016, 32, 1561-1565.	1.7	90
24	Autonomie Correlates of Antidepressant Treatment Using Heart-Rate Variability Analysis. Canadian Journal of Psychiatry, 1998, 43, 183-186.	1.9	84
25	Canadian Cardiovascular Society/Canadian Heart Rhythm Society 2016 Implantable Cardioverter-Defibrillator Guidelines. Canadian Journal of Cardiology, 2017, 33, 174-188.	1.7	84
26	Hypertrophic Cardiomyopathy–Related Sudden Cardiac Death in Young People in Ontario. Circulation, 2019, 140, 1706-1716.	1.6	82
27	A novel, simple scale for assessing the symptom severity of atrial fibrillation at the bedside: The CCS-SAF Scale. Canadian Journal of Cardiology, 2006, 22, 383-386.	1.7	79
28	Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. European Heart Journal, 2014, 35, 1897-1906.	2.2	78
29	Gender differences and quality of life in atrial fibrillation: The mediating role of depression. Journal of Psychosomatic Research, 2006, 61, 769-774.	2.6	77
30	Interpreting changes in quality of life in atrial fibrillation: How much change is meaningful?. American Heart Journal, 2013, 166, 381-387.e8.	2.7	76
31	Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation. Clinical Therapeutics, 2014, 36, 192-210.e20.	2.5	74
32	Outcomes of Implantable Cardioverter-Defibrillator Use in Patients With Comorbidities. JACC: Heart Failure, 2014, 2, 623-629.	4.1	72
33	Psychological Correlates of Quality of Life in Atrial Fibrillation. Quality of Life Research, 2006, 15, 1323-1333.	3.1	66
34	Warfarin and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation Receiving Dialysis: A Systematic Review and Meta-analysis. Canadian Journal of Cardiology, 2017, 33, 737-746.	1.7	58
35	Electrocardiograms in Low-Risk Patients Undergoing an Annual Health Examination. JAMA Internal Medicine, 2017, 177, 1326.	5.1	55
36	Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. European Heart Journal, 2020, 41, 347-356.	2.2	55

#	Article	IF	CITATIONS
37	Antiarrhythmic Action ofβ-Blockers: Potential Mechanisms. Journal of Cardiovascular Pharmacology and Therapeutics, 2005, 10, S15-S22.	2.0	54
38	Factors Associated With 90-Day Death After Emergency Department Discharge for Atrial Fibrillation. Annals of Emergency Medicine, 2013, 61, 539-548.e1.	0.6	53
39	Resuscitation Outcomes Consortium–Amiodarone, Lidocaine or Placebo Study (ROC-ALPS): Rationale and methodology behind an out-of-hospital cardiac arrest antiarrhythmic drug trial. American Heart Journal, 2014, 167, 653-659.e4.	2.7	53
40	Survival After Intravenous Versus Intraosseous Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Shock-Refractory Cardiac Arrest. Circulation, 2020, 141, 188-198.	1.6	53
41	Health-Related Quality of Life in Patients With Atrial Fibrillation Treated With Rhythm Control Versus Rate Control. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 896-904.	2.2	52
42	The prevalence of obstructive sleep apnea in patients with atrial fibrillation. Clinical Cardiology, 2018, 41, 601-607.	1.8	52
43	Outcomes for Emergency Department Patients With Recent-Onset Atrial Fibrillation and Flutter Treated in Canadian Hospitals. Annals of Emergency Medicine, 2017, 69, 562-571.e2.	0.6	51
44	COVID-19–Myocarditis and Return to Play: Reflections and Recommendations From a Canadian Working Group. Canadian Journal of Cardiology, 2021, 37, 1165-1174.	1.7	49
45	Major Adverse Cardiovascular Events Associated With Postoperative Atrial Fibrillation After Noncardiac Surgery. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007437.	4.8	49
46	Gender-Based Differences in Outcomes Among Resuscitated Patients With Out-of-Hospital Cardiac Arrest. Circulation, 2021, 143, 641-649.	1.6	45
47	The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Rehabilitation and Exercise and Surgical Coronary Revascularization. Canadian Journal of Cardiology, 2014, 30, 249-263.	1.7	44
48	Potential Cost-Effectiveness of Ambulatory Cardiac Rhythm Monitoring After Cryptogenic Stroke. Stroke, 2016, 47, 2380-2385.	2.0	43
49	Systematic review and network meta-analysis of stroke-prevention treatments in patients with atrial fibrillation. Clinical Pharmacology: Advances and Applications, 2016, Volume 8, 93-107.	1.2	35
50	Canadian Cardiovascular Society/Canadian Heart Rhythm Society Joint Position Statement on the Cardiovascular Screening of Competitive Athletes. Canadian Journal of Cardiology, 2019, 35, 1-11.	1.7	34
51	Triazolam and ethanol interaction: Kinetic and dynamic consequences. Clinical Pharmacology and Therapeutics, 1985, 37, 558-562.	4.7	32
52	Sleep Apnea Increases the Risk of New Hospitalized Atrial Fibrillation. Chest, 2018, 154, 1330-1339.	0.8	32
53	The American Heart Association 2010 Guidelines for the Management of Cardiac Arrest in Pregnancy: Consensus Recommendations on Implementation Strategies. Journal of Obstetrics and Gynaecology Canada, 2011, 33, 858-863.	0.7	30
54	Population Trends in All ause Mortality and Cause Specific–Death With Incident Atrial Fibrillation. Journal of the American Heart Association, 2020, 9, e016810.	3.7	30

#	Article	IF	CITATIONS
55	The Long-Term Use of Warfarin Among Atrial Fibrillation Patients Discharged From an Emergency Department With a Warfarin Prescription. Annals of Emergency Medicine, 2015, 66, 347-354.e2.	0.6	29
56	Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design. Canadian Journal of Cardiology, 2019, 35, 1069-1077.	1.7	27
57	Antiarrhythmic Drugs for Nonshockable-Turned-Shockable Out-of-Hospital Cardiac Arrest. Circulation, 2017, 136, 2119-2131.	1.6	26
58	The <scp>STOP</scp> â€ <scp>BANG</scp> questionnaire shows an insufficient specificity for detecting obstructive sleep apnea in patients with atrial fibrillation. Journal of Sleep Research, 2018, 27, e12702.	3.2	26
59	Living alone and cardiovascular disease outcomes. Heart, 2019, 105, 1087-1095.	2.9	26
60	Prehospital sodium bicarbonate use could worsen long term survival with favorable neurological recovery among patients with out-of-hospital cardiac arrest. Resuscitation, 2017, 119, 63-69.	3.0	25
61	Common wearable devices demonstrate variable accuracy in measuring heart rate during supraventricular tachycardia. Heart Rhythm, 2020, 17, 854-859.	0.7	25
62	Implantable cardioverterâ€defibrillators in heart failure patients with reduced ejection fraction and diabetes. European Journal of Heart Failure, 2018, 20, 1031-1038.	7.1	24
63	Factors associated with out-of-hospital cardiac arrest with pulseless electric activity: A population-based study. American Heart Journal, 2016, 177, 129-137.	2.7	23
64	Patient-Reported Outcomes in AtrialÂFibrillation Research. JACC: Clinical Electrophysiology, 2019, 5, 599-605.	3.2	23
65	Study of the Effects of Epinephrine on Cerebral Oxygenation and Metabolism During Cardiac Arrest and Resuscitation by Hyperspectral Near-Infrared Spectroscopy. Critical Care Medicine, 2019, 47, e349-e357.	0.9	23
66	Prescribing of oral anticoagulants in the emergency department and subsequent long-term use by older adults with atrial fibrillation. Cmaj, 2019, 191, E1345-E1354.	2.0	22
67	A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 21-28.	3.0	20
68	Meta-Analysis of Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin According to Time in Therapeutic Range in Atrial Fibrillation. American Journal of Cardiology, 2021, 140, 62-68.	1.6	20
69	A Clinical Decision Instrument for 30-Day Death After an Emergency Department Visit for Atrial Fibrillation: The Atrial Fibrillation in the Emergency Room (AFTER) Study. Annals of Emergency Medicine, 2015, 66, 658-668.e6.	0.6	19
70	The impact of hospital experience with out-of-hospital cardiac arrest patients on post cardiac arrest care. Resuscitation, 2017, 110, 169-175.	3.0	19
71	Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy—Are there predictors of appropriate therapy?. Heart Rhythm, 2021, 18, 63-70.	0.7	19
72	Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective. JAMA Cardiology, 2017, 2, 525.	6.1	18

#	Article	IF	CITATIONS
73	Cardiac effects of CPAP treatment in patients with obstructive sleep apnea and atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2019, 54, 289-297.	1.3	17
74	Transcutaneous T Wave Shock: A Universal Method for Ventricular Fibrillation Induction. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 2930-2935.	1.2	16
75	Predictors and clinical outcomes of inpatient versus ambulatory management after an emergency department visit for atrial fibrillation: A population-based study. American Heart Journal, 2016, 173, 161-169.	2.7	16
76	Canadian Cardiovascular Society Cardiovascular Screening of Competitive Athletes: The Utility of the Screening Electrocardiogram to Predict Sudden Cardiac Death. Canadian Journal of Cardiology, 2019, 35, 1557-1566.	1.7	16
77	Identifying Predictors of Cumulative Healthcare Costs in Incident Atrial Fibrillation: A Populationâ€Based Study. Journal of the American Heart Association, 2015, 4, .	3.7	15
78	Cerebral Hemodynamics and Metabolism During Cardiac Arrest and Cardiopulmonary Resuscitation Using Hyperspectral Near Infrared Spectroscopy. Circulation Journal, 2017, 81, 879-887.	1.6	15
79	Mortality Risk Increases With Clustered Ventricular Arrhythmias in Patients With Implantable Cardioverter-Defibrillators. JACC: Clinical Electrophysiology, 2020, 6, 327-337.	3.2	15
80	Defibrillation Current and Impedance are Determinants of Defibrillation Energy Requirements. PACE - Pacing and Clinical Electrophysiology, 1988, 11, 1996-2001.	1.2	14
81	The Risk Stratification and Stroke Prevention Therapy Care Gap in Canadian Atrial Fibrillation Patients. Canadian Journal of Cardiology, 2016, 32, 336-343.	1.7	14
82	Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis. Metabolism Open, 2020, 7, 100039.	2.9	14
83	Canadian Cardiovascular Society Quality Indicators for Heart Failure. Canadian Journal of Cardiology, 2016, 32, 1038.e5-1038.e9.	1.7	13
84	Atrial Fibrillation Clinics in Canada: A Nationwide Project Report. Canadian Journal of Cardiology, 2018, 34, 1219-1224.	1.7	13
85	The prevention and management of sudden cardiac arrest in athletes. Cmaj, 2019, 191, E787-E791.	2.0	13
86	"Presumed cardiac―arrest in children and young adults: A misnomer?. Resuscitation, 2017, 117, 73-79.	3.0	12
87	A clinical decision instrument to predict 30-day death and cardiovascular hospitalizations after an emergency department visit for atrial fibrillation: The Atrial Fibrillation in the Emergency Room, Part 2 (AFTER2) study. American Heart Journal, 2018, 203, 85-92.	2.7	12
88	Association Between Hospital Teaching Status and Outcomes After Out-of-Hospital Cardiac Arrest. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005349.	2.2	12
89	Near-Infrared Spectroscopy to Assess Cerebral Autoregulation and Optimal Mean Arterial Pressure in Patients With Hypoxic-Ischemic Brain Injury: A Prospective Multicenter Feasibility Study. , 2020, 2, e0217.		12
90	Healthcare costs and resource utilization associated with treatment of out-of-hospital cardiac arrest. Resuscitation, 2020, 153, 234-242.	3.0	12

#	Article	IF	CITATIONS
91	β-Blockers and Atrial Fibrillation: Hypertension and Other Medical Conditions Influencing Their Use. Canadian Journal of Cardiology, 2014, 30, S38-S41.	1.7	11
92	Improving stroke prevention therapy for patients with atrial fibrillation in primary care: protocol for a pragmatic, cluster-randomized trial. Implementation Science, 2016, 11, 159.	6.9	11
93	Shared Decision Making and the Cardiovascular Care of Athletes: Is It Time to Get Back in the Game?. Canadian Journal of Cardiology, 2020, 36, 941-944.	1.7	11
94	The Risk of Acute Kidney Injury with Oral Anticoagulants in Elderly Adults with Atrial Fibrillation. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1470-1479.	4.5	11
95	Exercise in hypertrophic cardiomyopathy: restrict or rethink. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 320, H2101-H2111.	3.2	10
96	Left Ventricular Fibrosis in Middle-Age Athletes and Physically Active Adults. Medicine and Science in Sports and Exercise, 2020, 52, 2500-2507.	0.4	10
97	Bystander interventions and survival after exercise-related sudden cardiac arrest: a systematic review. British Journal of Sports Medicine, 2022, 56, 410-416.	6.7	10
98	Effect of Time to Treatment With Antiarrhythmic Drugs on Return of Spontaneous Circulation in Shockâ€Refractory Outâ€ofâ€Hospital Cardiac Arrest. Journal of the American Heart Association, 2022, 11, e023958.	3.7	10
99	The Burden of Atrial Fibrillation: Should We Abandon Antiarrhythmic Drug Therapy?. Journal of Cardiovascular Pharmacology and Therapeutics, 2004, 9, 257-262.	2.0	9
100	Oral Anticoagulation for Stroke Prevention in Canadian Practice: Stroke Prevention and Rhythm Interventions in Atrial Fibrillation (SPRINT-AF) Registry*. Canadian Journal of Cardiology, 2016, 32, 204-210.	1.7	9
101	A Comparison of Two Nights of Ambulatory Sleep Testing in Arrhythmia Patients. Sleep Disorders, 2018, 2018, 1-6.	1.4	9
102	Field Implementation of Remote Ischemic Conditioning in ST-Segment–Elevation Myocardial Infarction: The FIRST Study. Canadian Journal of Cardiology, 2020, 36, 1278-1288.	1.7	9
103	A Systematic Review of the Risk of Motor Vehicle Collision in Patients With Syncope. Canadian Journal of Cardiology, 2021, 37, 151-161.	1.7	9
104	Clinically Important Drug–Drug Interactions Between Antiarrhythmic Drugs and Anticoagulants. Journal of Innovations in Cardiac Rhythm Management, 2019, 10, 3552-3559.	0.5	9
105	Use of Evidence-Based Therapy for Cardiovascular Risk Factors in Canadian Outpatients With Atrial Fibrillation. American Journal of Cardiology, 2017, 120, 582-587.	1.6	8
106	Characteristics and Evidence-Based Management of Stable Coronary Artery Disease Patients in Canada Compared With the Rest of the World: Insights From the CLARIFY Registry. Canadian Journal of Cardiology, 2014, 30, 132-137.	1.7	7
107	Association of prior β-blocker use and the outcomes of patients with out-of-hospital cardiac arrest. American Heart Journal, 2015, 170, 1018-1024.e2.	2.7	7
108	Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation. Clinical Therapeutics, 2015, 37, 2476-2488.e27.	2.5	7

#	Article	IF	CITATIONS
109	Cardiac Remodeling in Middle-Aged Endurance Athletes and Recreationally Active Individuals: Challenges in Defining the "Athlete's Heart― Journal of the American Society of Echocardiography, 2020, 33, 247-249.	2.8	7
110	Policies to Prevent Sudden Cardiac Death in Young Athletes: Challenging, But More Testing Is Not the Answer. Journal of the American Heart Association, 2020, 9, e016332.	3.7	7
111	Responding to Cardiac Arrest in the Community in the Digital Age. Canadian Journal of Cardiology, 2022, 38, 491-501.	1.7	7
112	Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients. Stroke, 2015, 46, 2830-2837.	2.0	6
113	ECG Features Associated With Adverse Cardiovascular Outcomes in Patients With Atrial Fibrillation: A Combined AFFIRM and AFâ€CHF Analysis. Journal of Cardiovascular Electrophysiology, 2016, 27, 404-413.	1.7	6
114	Implantable Cardioverter Defibrillator Implantation Rates After Out of Hospital Cardiac Arrest: Are the Rates Guideline-Concordant?. Canadian Journal of Cardiology, 2017, 33, 1266-1273.	1.7	6
115	Management of direct oral anticoagulant associated bleeding: Results of a multinational survey. Thrombosis Research, 2018, 163, 19-21.	1.7	6
116	A Gas-Powered, Patient-Responsive Automatic Resuscitator for Use in Acute Respiratory Failure: A Bench and Experimental Study. Respiratory Care, 2021, 66, 366-377.	1.6	6
117	Evaluation of the Risk of Stroke Without Anticoagulation Therapy in Men and Women With Atrial Fibrillation Aged 66 to 74 Years Without Other CHA ₂ DS ₂ -VASc Factors. JAMA Cardiology, 2021, 6, 918.	6.1	6
118	A Population-Based Method for the Estimation of Defibrillation Energy Requirements in Humans. Circulation, 1997, 96, 267-273.	1.6	6
119	Effective and efficient use of implantable defibrillators: Sometimes it's over when it's over. Cmaj, 2009, 180, 599-600.	2.0	5
120	Greater Mortality Risk Among Patients With Delayed Follow-up After Implantable Cardioverter Defibrillator Procedures. Canadian Journal of Cardiology, 2014, 30, 598-605.	1.7	5
121	Developing a Pan-Canadian Registry of Sudden Cardiac Arrest: Challenges and Opportunities. CJC Open, 2019, 1, 53-61.	1.5	5
122	High risk neighbourhoods: The effect of neighbourhood level factors on cardiac arrest incidence. Resuscitation, 2020, 149, 100-108.	3.0	5
123	Rhythm and rate control of atrial fibrillation in the emergency department – A large community-based observational study. Canadian Journal of Emergency Medicine, 2018, 20, 834-840.	1.1	5
124	Association of Diabetes Duration and Glycemic Control With Stroke Rate in Patients With Atrial Fibrillation and Diabetes: A Populationâ€Based Cohort Study. Journal of the American Heart Association, 2022, 11, e023643.	3.7	5
125	Validation of a Noninvasive Measure of Local Myocardial Repolarization in a Conscious Human Model: Journal of Cardiovascular Electrophysiology, 1999, 10, 1171-1179.	1.7	4
126	Association Between Patient and Physician Sex and Physician-Estimated Stroke and Bleeding Risks in Atrial Fibrillation. Canadian Journal of Cardiology, 2019, 35, 160-168.	1.7	4

#	Article	IF	CITATIONS
127	The Role of Quality of Life Indices in Patient-Centred Management of Arrhythmia. Canadian Journal of Cardiology, 2020, 36, 1022-1031.	1.7	4
128	Predicting Sudden Cardiac Death After Myocardial Infarction. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009422.	4.8	4
129	Impact of Choice of Prophylaxis on the Microbiology of Cardiac Implantable Electronic Device Infections: Insights From the Prevention of Arrhythmia Device Infection Trial (PADIT). Open Forum Infectious Diseases, 2021, 8, ofab513.	0.9	4
130	Clinical characteristics and outcomes of acute coronary syndrome patients with left anterior hemiblock. Heart, 2014, 100, 1456-1461.	2.9	3
131	Lack of difference in T wave variability between patients at risk of sudden cardiac death and healthy subjects. Journal of Electrocardiology, 2014, 47, 251-256.	0.9	3
132	Does location matter? A proposed methodology to evaluate neighbourhood effects on cardiac arrest survival and bystander CPR. Canadian Journal of Emergency Medicine, 2015, 17, 286-294.	1.1	3
133	Cardiac MRI and radionuclide ventriculography for measurement of left ventricular ejection fraction in ICD candidates. Magnetic Resonance Imaging, 2018, 52, 69-74.	1.8	3
134	Canada-wide mixed methods analysis evaluating the reasons for inappropriate emergency department presentation in patients with a history of atrial fibrillation: the multicentre AF-ED trial. BMJ Open, 2020, 10, e033482.	1.9	3
135	Impact of electrical cardioversion on quality of life for patients with symptomatic persistent atrial fibrillation: Is there a treatment expectation effect?. American Heart Journal, 2020, 226, 152-160.	2.7	3
136	Pattern of Atrial Fibrillation and Cognitive Function in Young Patients With Atrial Fibrillation and Low CHADS 2 Score: Insights From the BRAIN-AF Trial. Circulation: Arrhythmia and Electrophysiology, 2022, , CIRCEP121010462.	4.8	3
137	Establishing a multicenter, preclinical consortium in resuscitation: A pilot experimental trial evaluating epinephrine in cardiac arrest. Resuscitation, 2022, 175, 57-63.	3.0	3
138	Applying the Atrial Fibrillation Guidelines Update to Manage Your Patients With Atrial Fibrillation. Canadian Journal of Cardiology, 2014, 30, 1241-1244.	1.7	2
139	Assessing arrhythmia risk in a 15-year-old boy whose father died suddenly. Cmaj, 2016, 188, 1172-1174.	2.0	2
140	Symptoms and Quality of Life After AtrialÂFibrillation Ablation. JACC: Clinical Electrophysiology, 2017, 3, 1177-1179.	3.2	2
141	Avoiding Clinical Errors With Bedside Echocardiography: A Randomized Clinical Study. Canadian Journal of Cardiology, 2018, 34, 88-91.	1.7	2
142	Evaluating the 12-Lead Electrocardiogram for Diagnosing ARVC in Young Populations: Implications for Preparticipation Screening of Athletes. CJC Open, 2021, 3, 498-503.	1.5	2
143	Atrial structure and function in middleâ€aged, physicallyâ€active males and females: A cardiac magnetic resonance study. Clinical Cardiology, 2021, 44, 1467-1474.	1.8	2
144	Inadvertent Defibrillator Sense/Pace Lead Placement in the Middle Cardiac Vein: A Possible Complication with New Implications. PACE - Pacing and Clinical Electrophysiology, 1994, 17, 2349-2352.	1.2	1

#	Article	IF	CITATIONS
145	Regarding manuscript: "Resuscitation Outcomes Consortium–Amiodarone, Lidocaine, or Placebo study: Rationale and methodology behind out-of-hospital cardiac arrest antiarrhythmic drug trialâ€e American Heart Journal, 2014, 168, e19-e20.	2.7	1
146	Whom do you believe? The patient or the ECG?. Heart Rhythm, 2015, 12, 666-667.	0.7	1
147	Flecainide and elevated liver enzymes in $\hat{l}\pm 1$ -antitrypsin deficiency. HeartRhythm Case Reports, 2016, 2, 237-240.	0.4	1
148	Trials and tribulations: Antiarrhythmic drugs for the acute conversion of atrial fibrillation. Heart Rhythm, 2016, 13, 1784-1785.	0.7	1
149	Meta-Analysis Comparing Neurohumoral Antagonist Use in Patients ≥75 Years Versus <75 Years Receiving Cardiac Resynchronization Therapy. American Journal of Cardiology, 2018, 121, 975-980.	1.6	1
150	Out-of-Hospital Cardiac Arrest in the Presence of Ischemic Heart Disease: What Is the Long-term Arrhythmic Risk After Revascularization?. Canadian Journal of Cardiology, 2018, 34, 1079-1082.	1.7	1
151	The Potential Impact of Intrathoracic Impedance on Defibrillation Threshold Testing in S-ICDs. Canadian Journal of Cardiology, 2019, 35, 1604.e13-1604.e16.	1.7	1
152	Improving Resuscitation Rates After Out-of-Hospital Cardiac Arrest. Circulation, 2019, 139, 1272-1274.	1.6	1
153	Detecting Patients With Nonvalvular Atrial Fibrillation and Atrial Flutter in the Canadian Primary Care Sentinel Surveillance Network: First Steps. CJC Open, 2021, 3, 367-371.	1.5	1
154	Cardiac remodeling in middle-aged endurance athletes: relation between signal-averaged electrocardiogram and LV mass. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 320, H316-H322.	3.2	1
155	Symptoms in Atrial Fibrillation. JACC: Clinical Electrophysiology, 2021, 7, 575-577.	3.2	1
156	Wearables for cardiac monitoring in athletes: precious metal or fool's gold?. European Heart Journal Digital Health, 2021, 2, 358-360.	1.7	1
157	An Association Between Cardiologist Billing Patterns, Health Care Use, and Outcomes in Cardiac Patients. CJC Open, 2021, 3, 758-768.	1.5	1
158	A Novel Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Biomarker Anti-DSG2 is Absent in Athletes with Right Ventricular Enlargement. CJC Open, 2021, 3, 1413-1418.	1.5	1
159	Association of Cardiology Billing Amounts With Health Care Utilization and Clinical Outcomes in Patients With Atrial Fibrillation. Journal of the American Heart Association, 2021, 10, e020708.	3.7	1
160	Do Permanent Pacemakers Need an Insulative Coating? Results of a Prospective Randomized Double-Blind Study. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 2394-2397.	1.2	0
161	Applying the new STEMI guidelines: 2. Disturbances of cardiac rhythm after ST-segment elevation myocardial infarction. Cmaj, 2004, 171, 1042-1044.	2.0	0
162	A 26-year-old competitive soccer player with syncope. Cmaj, 2015, 187, 1225-1228.	2.0	0

#	Article	IF	CITATIONS
163	Federal leadership needed to realize national data set for cardiovascular care. Cmaj, 2017, 189, E1294-E1294.	2.0	0
164	Letter by Banks et al Regarding Article, "Does High-Intensity Endurance Training Increase the Risk of Atrial Fibrillation? A Longitudinal Study of Left Atrial Structure and Function― Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006645.	4.8	0
165	Interpreting observational data on adrenaline in cardiac arrest is complicated. Resuscitation, 2019, 138, 314-315.	3.0	0
166	Predicting Sudden Death in Dilated Cardiomyopathy: The Potential Power of Magnetic Resonance Imaging as a Critical Tool. Canadian Journal of Cardiology, 2020, 36, 1006-1008.	1.7	0
167	Response by Weissler-Snir and Dorian to Letter Regarding Article, "Hypertrophic Cardiomyopathy-Related Sudden Cardiac Death in Young People in Ontario― Circulation, 2020, 141, e703-e704.	1.6	0
168	Multi-centre implementation of an Educational program to improve the Cardiac Arrest diagnostic accuracy of ambulance Telecommunicators and survival outcomes for sudden cardiac arrest victims: the EduCATe study design and methodology. BMC Emergency Medicine, 2021, 21, 26.	1.9	0
169	Abstract 20190: Sudden Cardiac Death in the Young is Frequently Associated With Cardiac Disease and Drug Use. Circulation, 2014, 130, .	1.6	0
170	Myocardial strain assessment using cardiovascular magnetic resonance imaging in recipients of implantable cardioverter defibrillators. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 115.	3.3	0
171	Lifestyle modification for the management of atrial fibrillation. Cmaj, 2020, 192, E1469.	2.0	0